Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  NovoCure Limited    NVCR   JE00BYSS4X48

NOVOCURE LIMITED

(NVCR)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/18/2020 02/19/2020 02/20/2020 02/21/2020 02/24/2020 Date
95.01(c) 95.75(c) 92.94(c) 88.26(c) 83.8(c) Last
619 559 431 234 796 500 866 881 1 044 426 Volume
+1.99% +0.78% -2.93% -5.04% -5.05% Change
More quotes
Financials (USD)
Sales 2019 351 M
EBIT 2019 6,79 M
Net income 2019 -10,5 M
Finance 2019 26,5 M
Yield 2019 -
Sales 2020 450 M
EBIT 2020 55,1 M
Net income 2020 43,9 M
Finance 2020 109 M
Yield 2020 -
P/E ratio 2019 -815x
P/E ratio 2020 209x
EV / Sales2019 23,5x
EV / Sales2020 18,2x
Capitalization 8 294 M
More Financials
Company
NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the... 
More about the company
Surperformance© ratings of NovoCure Limited
Trading Rating : Investor Rating :
More Ratings
Latest news on NOVOCURE LIMITED
01/27Virus Hits Hong Kong as Economy Is Still Catching Its Breath After Unrest -- ..
DJ
01/21NOVOCURE : Announces National Reimbursement in Israel for Optune® in Combination..
BU
01/13NOVOCURE : Announces Fourth Quarter and Full Year 2019 Preliminary Net Revenues ..
BU
2019NOVOCURE : to Participate in the 38th Annual J.P. Morgan Healthcare Conference
BU
2019NOVOCURE : and the AACR Announce 2nd Annual AACR-Novocure : Grants for Tumor Tre..
BU
2019NOVOCURE : to Participate in the Evercore ISI 2019 HealthCONx Conference
BU
2019NOVOCURE : Announces 43 Presentations on Tumor Treating Fields at 24th Annual Me..
BU
2019NOVOCURE : Reports Third Quarter 2019 Financial Results and Provides Company Upd..
BU
2019NOVOCURE : Results from STELLAR Trial of Tumor Treating Fields with Chemotherapy..
BU
2019NOVOCURE : to Report Third Quarter 2019 Financial Results
BU
2019NOVOCURE : Announces 27 Presentations at the American Society for Radiation Onco..
BU
2019NOVOCURE : to Participate in Three Upcoming Investor Conferences
BU
2019NOVOCURE : Reports Second Quarter 2019 Financial Results and Provides Company Up..
BU
2019NOVOCURE : Announces 10 Oral Presentations and a Special Session on Tumor Treati..
BU
2019NOVOCURE : CMS Establishes 2019 Monthly Fee Schedule Amount for Optune®
BU
More news
News in other languages on NOVOCURE LIMITED
01/27VIRUS CHINOIS : le nombre de cas pourrait être supérieur à 40'000 (chercheurs)
2019NOVOCURE : Deutsches Institut für Qualität und Wirtschaftlichkeit im Gesundheits..
2019NOVOCURE : mit 13 Präsentationen und einem Symposium zu Tumortherapiefeldern auf..
2017NOVOCURE : JAMA veröffentlicht die Schlussanalyse der zulassungsrelevanten Phase..
2017NOVOCURE : Der Gemeinsame Bundesausschuss beschließt die Einleitung des Beratung..
More news
Sector news : Medical Equipment
02/21Pharmaceutical companies develop system to better track counterfeit drugs
RE
02/20FISHER & PAYKEL HEALTHCARE : F&P Healthcare Raises Fiscal Year Earnings, Revenue..
DJ
02/20SMITH & NEPHEW : +Nephew forecasts sales growth after best year since 2010
RE
02/18MEDTRONIC : Raises 2020 Guidance, Sets 4Q Outlook
DJ
02/18MEDTRONIC : 3Q Profit, Sales Rise
DJ
More sector news : Medical Equipment
Chart NOVOCURE LIMITED
Duration : Period :
NovoCure Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVOCURE LIMITED
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 90,43  $
Last Close Price 83,80  $
Spread / Highest target 25,3%
Spread / Average Target 7,91%
Spread / Lowest Target -5,73%
EPS Revisions
Managers
NameTitle
Asaf Danziger Chief Executive Officer & Director
William F. Doyle Executive Chairman
Michael J. Ambrogi Chief Operating Officer
Wilhelmus Groenhuysen Chief Financial & Accounting Officer
Uri Weinberg Vice President-Clinical Development
Sector and Competitors
1st jan.Capitalization (M$)
NOVOCURE LIMITED4.73%8 735
ABBOTT LABORATORIES0.68%154 212
MASIMO CORPORATION12.85%9 595
PENUMBRA, INC.16.95%6 708
ASAHI INTECC CO., LTD.0.33%6 386
GETINGE0.55%4 901